FDA-cleared profile

AI Segmentation

Varian Medical Systems, Inc.

AI Segmentation version 2.0 generates initial CT organ-at-risk contours for head and neck, thorax, abdomen, and pelvis for review, editing, and approval in Eclipse.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
AI Segmentation version 2.0 generates initial CT organ-at-risk contours for head and neck, thorax, abdomen, and pelvis for review, editing, and approval in Eclipse.
FDA source Exact FDA submission Checked 2026-09-03
Intended users
Qualified expert radiation-therapy treatment planners and approving physicians.
FDA source Exact FDA submission Checked 2026-09-03
Care setting and population
Radiation-oncology planning departments using compatible Eclipse workflows.
FDA source Exact FDA submission Checked 2026-09-03
Workflow role
Static cloud-based deep-learning and classical organ-at-risk contour generation with web review and simple editing.
Public source Exact FDA submission Checked 2026-09-03
Required input
DICOM CT images for radiation-therapy treatment planning.
FDA source Exact FDA submission Checked 2026-09-03
Output and human action
Reviewed organ-at-risk contours selected for export into Eclipse Treatment Planning System.
FDA source Exact FDA submission Checked 2026-09-03
Limitations
The application does not provide clinical decisions, medical advice, or treatment-plan evaluation. All contours require expert review, editing as needed, and physician approval; no animal or clinical study was performed.
FDA source Exact FDA submission Checked 2026-09-03

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K211881
FDA source Exact FDA submission Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
FDA source Exact FDA submission Checked 2026-09-03
Anatomy
Multi-region
FDA source Exact FDA submission Checked 2026-09-03
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2021-09-02
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Cloud web application integrated with Eclipse for contour export; validate DICOM routing, structure naming, image association, browser and identity controls, editing, approval, and downtime procedures.
Public source Exact FDA submission Checked 2026-09-03
Deployment and data flow
Software-only cloud application with a web interface and Eclipse integration; exact hosting, tenancy, region, identity, audit, and support architecture require vendor confirmation.
Public source Exact FDA submission Checked 2026-09-03
Security and privacy
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-03

Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request data-flow, identity, audit, encryption, retention, support-access, vulnerability-management, backup, and incident-response evidence.

Training and support
Only qualified expert radiation-therapy treatment planners and approving physicians. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-03
Monitoring and change control
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The application does not provide clinical decisions, medical advice, or treatment-plan evaluation. All contours require expert review, editing as needed, and physician approval; no animal or clinical study was performed.
Public source Exact FDA submission Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K211881 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Cloud web application integrated with Eclipse for contour export; validate DICOM routing, structure naming, image association, browser and identity controls, editing, approval, and downtime procedures.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The application does not provide clinical decisions, medical advice, or treatment-plan evaluation. All contours require expert review, editing as needed, and physician approval; no animal or clinical study was performed.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The application does not provide clinical decisions, medical advice, or treatment-plan evaluation. All contours require expert review, editing as needed, and physician approval; no animal or clinical study was performed.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
K211881 reports software verification and model-level Dice comparison against ground truth, literature values, or the prior model. Clinical experts also used a qualitative target of 80% of scores rating contours acceptable with minor or no adjustment; no sample sizes or organ-level results are disclosed.
Public source Exact FDA submission Checked 2026-09-03
Reported sensitivity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Expert acceptability target

80 %

Scores rated acceptable with minor or no adjustments in AI Segmentation.

Tested version: Varian AI Segmentation version 2.0

K211881 FDA performance package for AI Segmentation

Manufacturer nonclinical algorithm verification using Dice and expert qualitative acceptability scoring · CT organ-at-risk structures across head and neck, thorax, abdomen, and pelvis

exact submission · Tested version: Varian AI Segmentation version 2.0 · Sponsor or vendor study

K211881

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-03

No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
Public source Not applicable Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K211881 by exact submission identifier.
Public source Exact FDA submission Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
24Fields reviewed
7Source classes checked
20Unreviewed PubMed leads
5Unreviewed trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA materials, current product-family sources, selected clinical literature, reimbursement context, and exact-identifier recall candidates were reviewed. Pricing, contracted services, enabled options, final security architecture, and local interoperability remain organization-specific evidence. Automated exact-name discovery found 20 PubMed and 5 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-02.

Alternatives

Related tools to compare

FDA-cleared K230082

Auto Segmentation

GE Medical Systems, LLC

Auto Segmentation generates initial DICOM RT Structure Set contours for 40 organs or subregions from adult contrast or noncontrast CT across head and neck, thorax, abdomen, and...

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2023-05-04
FDA-cleared K203469

AI Segmentation

Varian Medical Systems, Inc.

AI Segmentation version 1.0 is a static, cloud-hosted web application that generates initial CT organ-at-risk contours for head and neck, thorax, abdomen, and pelvis for review...

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2021-04-19